Churchill Capital Corp XI

Good afternoon and welcome to the Chemocentrics fourth quarter and full year 2021 financial results conference call. At this time, all participants are in a listen-only mode. Later, we will conduct a question and answer session. As a reminder, this conference call will be recorded. And I would now like to turn the call over to Bill Slattery, Jr., Vice President of Investor Relations and Corporate Communications at Chemocentrics. Mr. Slattery. Please go ahead.

Thank you, operator. Good afternoon and welcome to the Chemocentrics fourth quarter and full year 2021 financial results conference call. For those of you I have not yet met, I recently joined Chemocentrics as head of investor relations and corporate communications. My contact information can be found at the bottom of the press release we issued earlier this afternoon, providing an overview of our financial results the quarter and year ended December 31st, 2021. This press release along with a slide deck that you may find helpful while you listen to this call are available on the investing relations section of our website at www.chemocentrics.com. Joining us on the call today from Chemocentrics are Dr. Thomas Schall, President, Chief Executive Officer, and Chairman of the Board, Susan Kanaya, Executive Vice President, Chief Financial and Administrative Officer, and Tasha Budd, Executive Vice President and Chief Operations Officer. Tom and Susan will make introductory remarks before we open the call to your questions. During today's call, we will be making certain forward-looking statements. As explained on slide two, These forward-looking statements are based on current information, assumptions, and expectations that are subject to change and involve a number of risks and uncertainties that may cause actual results to differ materially from those contained in the forward-looking statements. These risks are described in the company's filings made with the Securities and Exchange Commission, including our annual report on Form 10-K, filed on March 1, 2022. We are cautioned not to place undue reliance on these forward-looking statements, and Chemocentrics disclaims any obligation to update such statements. In addition, this conference call contains time-sensitive information that is accurate only as of the date of this live broadcast, March 1, 2022.

Chemocentrics undertakes no obligation to revise or update any forward-looking statements to reflect events or circumstances after the date of this live conference call.